Business Context and Reporting Period
Company: Onto Innovation Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: October 09, 2025
Subject: Amendment to the Equity Purchase Agreement for the acquisition of Semilab USA LLC.
Key Financial Metrics and Transaction Terms
This filing details a material amendment to a pending acquisition rather than reporting standard periodic financial results (revenue, profit, cash flow) for the company.
- Revised Purchase Price: $432,310,000 in cash (subject to adjustments) plus 641,771 shares of Onto Innovation common stock.
- Price Reduction: Approximately $50 million reduction from the original estimated value of $495 million (based on June 27, 2025 stock price).
- Excluded Business: The Fourier-Transform infrared spectroscopy reflectometry systems business (EIR Business) is excluded from the transaction.
- Excluded Revenue: The EIR Business represents approximately $13 million, or 10%, of estimated 2025 revenue for Semilab USA.
- Projected Acquired Revenue: The amended transaction targets approximately $120 million in annual revenue.
Material Changes Versus Prior Period
The primary material change is the restructuring of the acquisition agreement to address regulatory scrutiny:
- Regulatory Trigger: The U.S. Department of Justice (DOJ) issued a "Second Request" for additional information on September 25, 2025, extending the Hart-Scott-Rodino (HSR) waiting period.
- Strategic Adjustment: To expedite regulatory clearance, the parties agreed to divest the EIR Business from the scope of the acquisition.
- Regulatory Filing Status: The Company and Seller intend to withdraw existing HSR filings and submit new notifications to the DOJ and Federal Trade Commission (FTC) reflecting the amended terms.
Guidance, Outlook, and Risks
Management Commentary and Outlook:
- EPS Impact: The amended transaction is expected to increase earnings per share by approximately 10% in the first year following closing.
- Timing: The Company continues to anticipate the transaction will be completed in 2025.
- Existing Guidance: The Company affirms its third-quarter guidance initially provided on August 7, 2025.
Risks and Contingencies:
- Regulatory Approval: Closing remains subject to the expiration or termination of the HSR waiting period; approval is not guaranteed.
- Transaction Failure: Risks include the inability to satisfy closing conditions, delays in integration, or failure to realize anticipated synergies.
- Operational Disruption: Potential adverse effects on customer relationships, employee retention, and management focus due to the ongoing transaction process.
Investor Verification Checklist
- Verify the status of the new HSR notification filings with the DOJ and FTC.
- Confirm the final closing date and whether the 2025 completion target remains viable given the regulatory timeline.
- Review the specific terms of the purchase price adjustments and the valuation of the 641,771 common stock shares at closing.
- Monitor for any further regulatory conditions or divestitures required to secure approval.
- Assess the integration plan for the remaining Semilab USA assets to ensure the projected 10% EPS accretion is achievable.